Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Hemanext is raising $44,470,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Martin Cannon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hemanext

Hemanext is a medical technology company with corporate headquarters in Lexington, MA and manufacturing operations in Avon, MA. Our corporate mission is to support the transfusion medicine community in its efforts to save lives and improve patient outcomes. Our distinctive focus is on innovations that promote radical improvements in the quality, safety, efficacy and cost of transfusion therapy.

To learn more about Hemanext, visit http://www.hemanext.com/

Contact:
Martin Cannon, President and Chief Executive Officer
781-301-7474
https://www.linkedin.com/in/martincannon1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved